RFG Advisory’s Novartis NVS Stock Holding History

RFG Advisory’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$762K	Buy	4,861 +1,269	+35%	+$190K	0.01%	671
2026 Q1	$549K	Buy	3,592 +1,329	+59%	+$204K	0.01%	706
2025 Q4	$312K	Buy	+2,263	New	+$296K	0.01%	835
2025 Q1	–	Sell	-8,617	Closed	-$839K	–	889
2024 Q4	$839K	Sell	8,617 -3,350	-28%	-$357K	0.02%	404
2024 Q3	$1.38M	Buy	+11,967	New	+$1.36M	0.04%	315
2021 Q1	–	Sell	-2,152	Closed	-$202K	–	451
2020 Q4	$202K	Buy	+2,152	New	+$188K	0.03%	412
2020 Q1	–	Sell	-2,321	Closed	-$220K	–	390
2019 Q4	$220K	Buy	+2,321	New	+$208K	0.04%	329
2018 Q4	–	Sell	-2,624	Closed	-$203K	–	298
2018 Q3	$203K	Buy	+2,624	New	+$194K	0.05%	282
2018 Q2	–	Sell	-3,171	Closed	-$230K	–	237
2018 Q1	$230K	Buy	3,171 +335	+12%	+$25.5K	0.09%	172
2017 Q4	$219K	Sell	2,836 -71	-2%	-$5.36K	0.1%	169
2017 Q3	$223K	Sell	2,907 -737	-20%	-$55.7K	0.14%	148
2017 Q2	$268K	Buy	3,644 +196	+6%	+$13.9K	0.18%	108
2017 Q1	$228K	Buy	+3,448	New	+$230K	0.17%	122

Other funds holding NVS

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GGI

Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

RFG Advisory's NVS Position: Q2 2026 in Review

RFG Advisory increased its Novartis (NVS) stake by 35% in Q2 2026, buying an estimated $190K and bringing the position to 4,861 shares worth $762K. The position accounts for 0.01% of the portfolio, ranked #671.

RFG Advisory first reported a position in NVS in Q1 2017 and has held it in 13 quarters since. The position peaked at $1.38M in Q3 2024. 509 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

RFG Advisory held 4,861 shares of Novartis worth $762K as of Q2 2026.
RFG Advisory bought 1,269 Novartis shares in Q2 2026, an estimated $190K.
Novartis made up 0.01% of RFG Advisory's portfolio in Q2 2026, its #671 holding.
RFG Advisory first reported a position in Novartis in Q1 2017 and has held it in 13 quarters since.
RFG Advisory's Novartis position peaked at $1.38M in Q3 2024.
509 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.